TY - JOUR
AU - Brinkmann, Berit J
AU - Floerchinger, Alessia
AU - Schniederjohann, Christina
AU - Roider, Tobias
AU - Coelho, Mariana
AU - Mack, Norman
AU - Bruch, Peter-Martin
AU - Liebers, Nora
AU - Dötsch, Sarah
AU - Busch, Dirk H
AU - Schmitt, Michael
AU - Neumann, Frank
AU - Roessner, Philipp M
AU - Seiffert, Martina
AU - Dietrich, Sascha
TI - CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
JO - Blood
VL - 144
IS - 7
SN - 0006-4971
CY - Washington, DC
PB - American Society of Hematology
M1 - DKFZ-2024-01152
SP - 784-789
PY - 2024
N1 - 2024 Aug 15;144(7):784-789
AB - Anti-CD19 chimeric antigen receptor T-cells (CD19-CAR) represent an effective treatment for relapsed/refractory B-cell malignancies but incomplete responses often result in early disease progression. We here assessed potential benefits of co-administering CD20-targeting bispecific antibodies (CD20-BsAb) with CD19-CAR, aiming to enhance immunotherapeutic efficacy. Addition of CD20-BsAb to co-cultures of CD19-CAR and primary samples of B-cell malignancies, comprising malignant B- and endogenous T-cells, significantly improved killing of malignant cells alongside enhanced expansion of both endogenous T-cells and CD19-CAR. CD20-BsAb induced an increase in proliferation and activation of endogenous T-cells and CD19-CAR. In an immunocompetent mouse model of CLL, relapse after initial treatment response frequently occurred after CD19-CAR monotherapy. Combination with injections of CD20-BsAb significantly enhanced treatment response and resulted in improved eradication of malignant cells. Higher efficacy was accompanied by improved T-cell expansion upon CD20-BsAb administration and resulted in longer survival, with 80
LB - PUB:(DE-HGF)16
C6 - pmid:38805637
DO - DOI:10.1182/blood.2023022682
UR - https://inrepo02.dkfz.de/record/290535
ER -